司库奇尤单抗（抗白细胞介素-17A治疗性抗体）改善了混合型CRS的临床结局。
Secukinumab (Anti-IL-17A Therapeutic Antibody) Improves Clinical Outcome for a Mixed Endotype CRS.
作者信息
Plaas Mihkel, Brazovskaja Agnieska, Kisand Kai, Tserel Liina, Peterson Pärt
机构信息
Ear Clinic Tartu University Hospital Tartu Estonia.
Institute of Clinical Medicine University of Tartu Tartu Estonia.
出版信息
Clin Case Rep. 2024 Dec 9;12(12):e9692. doi: 10.1002/ccr3.9692. eCollection 2024 Dec.
Abstract
We identified two CRSwNP patients who had previously failed treatment with an anti-IL-4/IL-13 antibody (dupilumab). Based on their clinical characteristics and blood cytokine levels, we considered them mixed Type II/Type III cases and treated them with an anti-IL-17 antibody (secukinumab). Anti-IL-17 antibody secukinumab was superior in reducing their NPS and SNOT-22 values compared to dupilumab. IL-17 could be a promising target for non-type II and mixed endotype CRS treatment.
摘要
我们识别出两名先前使用抗IL-4/IL-13抗体（度普利尤单抗）治疗失败的慢性鼻-鼻窦炎伴鼻息肉（CRSwNP）患者。根据他们的临床特征和血液细胞因子水平，我们认为他们属于II型/III型混合病例，并使用抗IL-17抗体（司库奇尤单抗）对他们进行治疗。与度普利尤单抗相比，抗IL-17抗体司库奇尤单抗在降低他们的鼻息肉评分（NPS）和鼻窦症状测试-22（SNOT-22）值方面更具优势。IL-17可能是治疗非II型和混合型内型CRS的一个有前景的靶点。
相似文献
1
Secukinumab (Anti-IL-17A Therapeutic Antibody) Improves Clinical Outcome for a Mixed Endotype CRS.司库奇尤单抗（抗白细胞介素-17A治疗性抗体）改善了混合型CRS的临床结局。
Clin Case Rep. 2024 Dec 9;12(12):e9692. doi: 10.1002/ccr3.9692. eCollection 2024 Dec.
2
Efficacy of dupilumab on chronic rhinosinusitis with nasal polyps and concomitant asthma in biologic-naive and biologic-pretreated patients.度普利尤单抗治疗生物制剂初治和生物制剂预处理的慢性鼻-鼻窦炎伴鼻息肉和哮喘患者的疗效。
Ann Med. 2024 Dec;56(1):2411018. doi: 10.1080/07853890.2024.2411018. Epub 2024 Oct 4.
3
Real-World Evaluation of Dupilumab in the Long-Term Management of Eosinophilic Chronic Rhinosinusitis with Nasal Polyps: A Focus on IL-4 and IL-13 Receptor Blockade.度普利尤单抗在嗜酸性粒细胞性慢性鼻-鼻窦炎伴鼻息肉长期管理中的真实世界评估：聚焦于白细胞介素-4和白细胞介素-13受体阻断
Medicina (Kaunas). 2024 Dec 3;60(12):1996. doi: 10.3390/medicina60121996.
4
Pathogenesis-based application of biologics for chronic rhinosinusitis: Current and future perspectives.基于发病机制的生物制剂在慢性鼻-鼻窦炎中的应用：现状与未来展望。
Auris Nasus Larynx. 2024 Apr;51(2):371-378. doi: 10.1016/j.anl.2023.08.005. Epub 2023 Sep 22.
5
Effects of inflammatory endotypes on disease trajectory in chronic rhinosinusitis with nasal polyps.炎症内型对伴鼻息肉慢性鼻-鼻窦炎疾病进程的影响。
J Allergy Clin Immunol. 2025 Jul;156(1):139-149.e4. doi: 10.1016/j.jaci.2025.03.029. Epub 2025 Apr 10.
6
Biologics in Chronic Rhinosinusitis: Current and Emerging.慢性鼻-鼻窦炎中的生物制剂：现状与展望
Immunol Allergy Clin North Am. 2024 Nov;44(4):657-671. doi: 10.1016/j.iac.2024.07.005. Epub 2024 Aug 17.
7
Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: A real-world study.生物疗法治疗哮喘对并存的慢性鼻-鼻窦炎的益处：一项真实世界研究。
Int Forum Allergy Rhinol. 2021 Aug;11(8):1152-1161. doi: 10.1002/alr.22774. Epub 2021 Feb 1.
8
Sleep quality burden in chronic rhinosinusitis with nasal polyps and its modulation by dupilumab.慢性鼻-鼻窦炎伴鼻息肉患者的睡眠质量负担及其受度普利尤单抗的调节。
Ann Allergy Asthma Immunol. 2024 Jan;132(1):69-75. doi: 10.1016/j.anai.2023.08.594. Epub 2023 Aug 29.
9
Comparison between clinical and cytological findings in chronic rhinosinusitis with nasal polyps treated with Dupilumab.比较度普利尤单抗治疗慢性鼻-鼻窦炎伴鼻息肉的临床和细胞学发现。
Eur Arch Otorhinolaryngol. 2024 Dec;281(12):6511-6521. doi: 10.1007/s00405-024-08958-6. Epub 2024 Sep 16.
10
IL-13 and IL-13-induced periostin levels are specifically decreased in patients following endoscopic sinus surgery for chronic rhinosinusitis.IL-13 和 IL-13 诱导的骨膜蛋白水平在慢性鼻-鼻窦炎患者经内镜鼻窦手术后特异性降低。
J Allergy Clin Immunol. 2024 May;153(5):1292-1305. doi: 10.1016/j.jaci.2023.11.922. Epub 2023 Dec 28.
引用本文的文献
1
Gastrointestinal Dysfunction and Dysbiosis in Ischemic Stroke: Opportunities for Therapeutic Intervention.缺血性卒中中的胃肠功能障碍与肠道菌群失调：治疗干预的机会
Pharmaceuticals (Basel). 2025 Feb 25;18(3):320. doi: 10.3390/ph18030320.
本文引用的文献
1
Real-world effectiveness of dupilumab in a European cohort of chronic rhinosinusitis with nasal polyps (CHRINOSOR).度普利尤单抗在欧洲慢性鼻-鼻窦炎伴鼻息肉队列（CHRINOSOR）中的真实世界疗效
J Allergy Clin Immunol. 2025 Feb;155(2):451-460. doi: 10.1016/j.jaci.2024.10.016. Epub 2024 Oct 31.
2
Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience.度普利尤单抗治疗伴鼻息肉的慢性鼻-鼻窦炎：西西里岛多中心真实世界数据
Am J Otolaryngol. 2024 Jan-Feb;45(1):104106. doi: 10.1016/j.amjoto.2023.104106. Epub 2023 Nov 5.
3
Role of IL-17A in Chronic Rhinosinusitis With Nasal Polyp.白细胞介素-17A在伴鼻息肉的慢性鼻-鼻窦炎中的作用
Allergy Asthma Immunol Res. 2020 May;12(3):507-522. doi: 10.4168/aair.2020.12.3.507.
4
European Position Paper on Rhinosinusitis and Nasal Polyps 2020.欧洲鼻窦炎和鼻息肉 2020 年立场文件。
Rhinology. 2020 Feb 20;58(Suppl S29):1-464. doi: 10.4193/Rhin20.600.
5
Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis.利用表型、内型和炎症标志物指导慢性鼻-鼻窦炎的治疗决策。
Ann Allergy Asthma Immunol. 2020 Apr;124(4):318-325. doi: 10.1016/j.anai.2020.01.013. Epub 2020 Jan 30.
6
Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis.慢性鼻-鼻窦炎的炎症表型与临床表现的相关性。
J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2812-2820.e3. doi: 10.1016/j.jaip.2019.05.009. Epub 2019 May 22.
7
IL-17 cytokines in immunity and inflammation.免疫与炎症中的白细胞介素-17细胞因子
Emerg Microbes Infect. 2013 Sep;2(9):e60. doi: 10.1038/emi.2013.58. Epub 2013 Sep 18.
Zotero 插件